Best Healthcare Sector ETFs in 2026

How We Chose These ETFs

Selecting the right ETFs for healthcare sector investors requires a careful evaluation of multiple factors. We analyzed dozens of funds across the industry and narrowed our recommendations based on the following criteria. Each factor was weighted according to its importance for investors in this specific category, ensuring that our picks are truly optimized for your goals.

1. Defensive sector that — Defensive sector that performs relatively well during economic downturns
2. Long-term growth driven — Long-term growth driven by aging populations and medical innovation
3. Diversification across pharma, — Diversification across pharma, biotech, devices, and insurance
4. Both income and — Both income and growth opportunities within the sector

We also factored in our proprietary Beginner Suitability Score, which evaluates each fund on a 1-to-10 scale considering expense ratios, volatility (beta), diversification (holdings count), dividend history, and track record length. Funds that score consistently high across these dimensions earned a spot on our list.

1. Health Care Select Sector SPDR Fund (XLV) — Best Overall

State Street Global Advisors • Health Care Sector

XLV provides targeted exposure to the health care sector of the S&P 500, including pharmaceutical giants, biotech firms, medical device makers, and health insurance companies. Healthcare is considered a defensive sector because people need medical care regardless of the economy. Beginners use XLV to add healthcare exposure, which can provide stability during market downturns while benefiting from long-term demographic trends like an aging population.

Health Care Select Sector SPDR Fund earns its spot as our best overall pick because it delivers on the metrics that matter most for healthcare sector investors. With an expense ratio of just 0.09%, you keep more of your returns working for you over time. The fund manages $40.0B in total assets, which speaks to its popularity and ensures strong liquidity with tight bid-ask spreads when you buy or sell shares.

Over the past five years, XLV has delivered a total return of 9.80%, outperforming many of its peers and rewarding patient, long-term investors. The fund holds 64 individual securities, giving you focused exposure to a curated selection of holdings. Its beta of 0.72 indicates that the fund is significantly less volatile than the broader market, making it a more stable choice for conservative investors.

XLV currently pays a dividend yield of 1.50%, providing investors with a stream of regular income on top of capital appreciation. Dividends are typically distributed quarterly and can be automatically reinvested through most major brokerages, accelerating the compounding process. With a track record stretching back to 1998, XLV has weathered multiple market cycles including the 2008 financial crisis and the 2020 pandemic, proving its resilience. Our Beginner Suitability Score rates it 9/10 (Great for Beginners), reflecting its excellent combination of low costs, manageable volatility, and broad diversification.

Comparison Table

Here is a side-by-side comparison of all 1 ETFs in our healthcare sector category. This table highlights the key metrics you should evaluate when choosing between these funds. Pay close attention to expense ratios and beginner scores, as these are the most impactful factors for long-term investment success.

*Beginner Score is calculated based on expense ratio, beta, holdings count, dividend yield, and fund inception year. Past performance does not guarantee future results.

Common Mistakes Healthcare Sector Investors Make

Even with a solid selection of ETFs, investors in the healthcare sector category can undermine their results by falling into avoidable traps. Understanding these common pitfalls will help you stay on track and avoid costly errors that could set back your financial progress by years or even decades.

• 1

  Concentrating in speculative biotech: Concentrating in speculative biotech companies without understanding the risks

• 2

  Ignoring the regulatory and: Ignoring the regulatory and political risks that affect healthcare stocks

• 3

  Overreacting to drug trial: Overreacting to drug trial failures in biotechnology holdings

• 4

  Not distinguishing between defensive: Not distinguishing between defensive healthcare and high-risk biotech

The best defense against these mistakes is a simple, written investment plan that you commit to following regardless of market conditions. Define your target allocation, set up automatic contributions, and schedule a review only once or twice per year. This removes emotion from the process and keeps you focused on long-term wealth building rather than short-term noise.

Frequently Asked Questions